Why the study?
Does extended anticoagulation with apixaban reduce the risk of recurrent venous thromboembolism?
Does extended anticoagulation with apixaban reduce the risk of recurrent venous thromboembolism?
Extended anticoagulation with apixaban (2.5 mg or 5 mg) effectively reduces recurrent VTE risk without increasing major bleeding.
Supports extended apixaban for secondary VTE prevention; extends RCT evidence for both doses in long-term management.
Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg) reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding. (Funded by Bristol-Myers Squibb and Pfizer; AMPLIFY-EXT ClinicalTrials.gov number, NCT00633893.).
No takes yet. Share an insight, caveat, or question.
Agnelli et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: